By Sahil Pandey Sept 24 (Reuters) - Acadia Pharmaceuticals said on Thursday its experimental drug for psychosis associated with Alzheimer's disease missed the main goal of a mid-stage study, sending ...
Captain Chesley "Sully" Sullenberger and wife Lorrie reveal the subtle behavioral shifts noticed years before his Alzheimer's ...
Capt. Chesley "Sully" Sullenberger revealed his greatest concern after his Alzheimer's disease diagnosis is that this is his ...
Census data shows 7 in 10 Miami-Dade seniors are Hispanic, a community already hit harder by Alzheimer's than others.
Researchers believe hearing loss may make the brain work harder. At the cost of thinking and memory, it can also lead people ...
Evidence for medically transmitted amyloid pathology is mounting, but whether Alzheimer’s disease itself can be transmitted — ...
Researchers hope the findings of new research could be used to develop treatments in the future.
Acadia Pharmaceuticals’ phase 2 Alzheimer’s disease trial has missed its primary endpoint, but the company and analysts alike ...
Alzheimer’s R&D is shifting toward disease modification, with amyloid, tau, RNA and immune targets driving trials, partnerships and oral therapy opportunities.Dublin, Sept. (GLOBE NEWSWIRE) -- ...
Acadia stock tumbled Thursday after the company's experimental Alzheimer's disease psychosis treatment missed the mark.
While Acadia Pharmaceuticals’ candidate has missed the main goal of a Phase 2 trial, the company is still moving forward with the anti-psychosis candidate in Alzheimer’s disease as well as Lewy body ...
The latest approvals expand the population of people who could be tested for the memory disorder—but experts warn the tests aren't for everyone.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results